Skip to main content
Livermore
Livermore
ZHEN

Enliven Therapeutics, Inc.

ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001672619

In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.

Holders of 5% or more of ELVN

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Enliven Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ELVN
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A13.30%7.87M shares–Nov 5, 20251 filingNov 5, 2025SEC
OrbiMed Advisors LLC13D/A9.50%6.77M shares−1.43 ppfrom 10.93%Jun 17, 20253 filingsJun 24, 2026SEC
Polar Capital Holdings Plc13G/A8.46%5.06M shares0.00 ppfrom 8.46%Feb 14, 20255 filingsJun 22, 2026SEC
Commodore Capital LP13G/A7.70%4.80M shares−2.20 ppfrom 9.90%Aug 14, 20252 filingsMay 15, 2026SEC
Vestal Point Capital, LP13G/A5.40%3.25M shares−1.10 ppfrom 6.50%Feb 17, 20262 filingsMay 15, 2026SEC
BlackRock, Inc.13G/A5.10%2.94M shares–Jul 17, 20251 filingJul 17, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

19 Schedule 13D and 13G filings on Enliven Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ELVN
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jun 24, 20267:15 PM ETOrbiMed Advisors LLCand 3 others13D/A9.50%6.77M shares−1.43 ppfrom 10.93%Jun 22, 2026SEC
Jun 22, 20269:29 AM ETPolar Capital Holdings Plcand 2 others13G/A8.46%5.06M shares0.00 ppfrom 8.46%Mar 31, 2026SEC
Jun 17, 20267:41 PM ETOrbiMed Advisors LLCand 3 others13D/A10.93%7.63M shares−2.47 ppfrom 13.40%Jun 15, 2026SEC
May 15, 20265:26 PM ETPolar Capital Holdings Plcand 2 others13G/A8.46%5.06M shares−0.01 ppfrom 8.47%Mar 31, 2026SEC
May 15, 20265:05 PM ETVestal Point Capital, LPand 1 other13G/A5.40%3.25M shares−1.10 ppfrom 6.50%Mar 31, 2026SEC
May 15, 20264:35 PM ETVenrock Healthcare Capital Partners III, L.P.and 6 others13G/A2.80%1.73M shares−2.60 ppfrom 5.40%Below 5%Mar 31, 2026SEC
May 15, 20264:31 PM ETFairmount Funds Management LLCand 3 others13G/A3.10%1.86M shares−3.20 ppfrom 6.30%Below 5%Mar 31, 2026SEC
May 15, 20264:30 PM ETCommodore Capital LPand 3 others13G/A7.70%4.80M shares−2.20 ppfrom 9.90%Mar 31, 2026SEC
May 15, 20269:12 AM ETPolar Capital Holdings Plcand 2 others13G/A8.47%59.8M shares+3.30 ppfrom 5.17%Mar 31, 2026SEC
Feb 17, 20264:07 PM ETVestal Point Capital, LPand 1 other13G6.50%3.83M sharesNewDec 31, 2025SEC
Nov 14, 20255:32 PM ETVenrock Healthcare Capital Partners III, L.P.and 6 others13G/A5.40%3.23M shares–Sep 30, 2025SEC
Nov 5, 202511:35 AM ETFMR LLCand 1 other13G/A13.30%7.87M shares–Sep 30, 2025SEC
Aug 14, 20255:06 PM ETCommodore Capital LPand 3 others13G/A9.90%6.02M shares–Jun 30, 2025SEC
Aug 14, 20254:03 PM ETFairmount Funds Management LLCand 3 others13G/A6.30%3.71M shares−0.30 ppfrom 6.60%Jun 30, 2025SEC
Aug 14, 20258:01 AM ETPolar Capital Holdings Plcand 2 others13G5.17%2.54M shares+0.28 ppfrom 4.89%Jun 30, 2025SEC
Jul 17, 20257:54 PM ETBlackRock, Inc.13G/A5.10%2.94M shares–Jun 30, 2025SEC
Jun 17, 20255:30 PM ETOrbiMed Advisors LLCand 3 others13D/A13.40%7.92M shares–Jun 16, 2025SEC
Feb 14, 20253:45 PM ETFairmount Funds Management LLCand 3 others13G/A6.60%3.20M shares–Dec 31, 2024SEC
Feb 14, 20259:17 AM ETPolar Capital Holdings Plcand 2 others13G/A4.89%2.39M shares–Below 5%Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Enliven Therapeutics, Inc. shares.

No Form 144 notices for Enliven Therapeutics, Inc. are on file.